Andrew X. Zhu, MD, PhD, on HCC: Results From KEYNOTE-224
2018 Gastrointestinal Cancers SymposiumAndrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses study findings on pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (Abstract 209).
Related Videos
Ramesh K. Ramanathan, MD, on Metastatic Pancreatic Cancer: Results From a SWOG Study
Ramesh K. Ramanathan, MD, of the Mayo Clinic, discusses early-phase study findings on mFOLFIRINOX (mFFOX) plus pegylated recombinant human hyaluronidase vs mFFOX alone in patients ...
Khaldoun Almhanna, MD, MPH, on Gastric Cancer: Results From the CCOG 1102 Trial
Khaldoun Almhanna, MD, MPH, of the H. Lee Moffitt Cancer Center, discusses the long-term outcome of a phase III study that explored the significance of extensive intraoperative per...
Kyaw L. Aung, MBBS, PhD, on Pancreatic Cancer: Results From the COMPASS Trial
Kyaw L. Aung, MBBS, PhD, of Princess Margaret Cancer Centre, discusses early study findings on genomics-driven precision medicine for advanced pancreatic ductal carcinoma (Abstract...
Steven D. Leach, MD, on Pancreatic Cancer: Keynote Lecture
Steven D. Leach, MD, of Dartmouth University’s Norris Cotton Cancer Center, discusses the personalized approach that GI cancers will require to make rational use of immunotherapy—i...
Maria Svensson, MD, PhD Candidate, on Esophageal and Gastric Cancers: Significance of PD-1 and PD-L1 Expression
Maria Svensson, MD, PhD Candidate, of Lund University, discusses high expression of PD-1 and PD-L1 in chemotherapy-naive esophageal and gastric adenocarcinomas, the implicati...
